Rounds in biotech & life sciences

46 rounds by Swiss startups in this sector, from newest to oldest. Investors, upcoming dates and neighbouring sectors: see the sector on the map.

November 2026

October 2026

  • DecodeNAture

    DecodeNAture rapidly identifies DNA in the field for agriculture, biosecurity and biodiversity monitoring.

    Prize · Lausanne · Biotech & life sciences · MassChallenge CH

    CHF 10,000
  • Topadur Pharma

    Topadur Pharma develops locally acting small molecules for wound healing and fibrosis, including TOP-N53, which is in phase 2a.

    Undisclosed round · Biotech & life sciences · DEBRA Research

    Amount not disclosed
  • Biodelphis Therapeutics

    Biodelphis Therapeutics, an EPFL spin-off, couples a small molecule with an antibody to treat osteoporosis without acting on the whole body.

    Loan · Lausanne · Biotech & life sciences · FIT Vaud (Innovaud)

    CHF 100,000
  • Atlas Bio

    Atlas Bio uses AI to simulate clinical trials and drug behaviour, in order to replace part of phase II trials and animal testing.

    Seed · Basel · Biotech & life sciences · Creandum

    USD 10 M
  • Juturna Bio

    Juturna Bio, an EPFL spin-off based at the Campus Biotech, is developing epigenetic therapies to restore the function of ageing brain cells, with Alzheimer's as the first target.

    Grant · Geneva · Biotech & life sciences · FIF Genève

    CHF 50,000
  • Nouscom

    Nouscom is developing NOUS-209, a neoantigen-based immunotherapy designed to prevent cancers in carriers of Lynch syndrome.

    Series C and later · Basel · Biotech & life sciences · M Ventures, Revelation Partners, Angelini Industries and 12 more

    USD 135 M

September 2026

August 2026

July 2026

June 2026

May 2026

  • NUCLIDIUM

    NUCLIDIUM develops copper-based radiotheranostics for cancer diagnosis and treatment.

    Series B · Basel · Biotech & life sciences · Kurma Growth Opportunities Fund, Angelini Ventures, Aurea and 6 more

    CHF 26 M
  • Windward Bio

    Windward Bio develops antibodies against immunological diseases, including WIN378, an anti-TSLP in phase 2/3 testing in asthma.

    Undisclosed round · Basel · Biotech & life sciences · OrbiMed, Novo Holdings, Blue Owl Healthcare Opportunities and 10 more

    USD 165 M
  • BioCopy

    BioCopy develops TCR-mimetic bispecific antibodies against cancer, with an R&D site in Emmendingen, Germany.

    Series A · Basel · Biotech & life sciences

    CHF 9 M

April 2026

March 2026

January 2026

  • FluoSphera

    FluoSphera has developed an in vitro platform that combines up to seven human tissue models in a single well to predict drug efficacy and toxicity.

    Undisclosed round · Geneva · Biotech & life sciences · Soulmates Ventures, IndieBio New York

    CHF 1.2 M
  • TECregen

    Founded in 2023, TECregen develops biologics aimed at regenerating the thymus to restore immune function.

    Seed · Basel · Biotech & life sciences · Boehringer Ingelheim Venture Fund (BIVF), LifeSpan Vision Ventures, Carma Fund and 4 more

    CHF 10 M

December 2025

November 2025